Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist primarily utilized for weight management, appetite suppression, and glycemic control. While clinical protocols typically involve weekly subcutaneous doses ranging from 2.5 mg to 15 mg, community users report a wide spectrum of dosing practices. Users frequently report side effects including edema, fluid retention, and gastrointestinal distress, though these remain limited in total volume. Readers should note that while the evidence for weight loss and diabetes is robust, the broader body of research for exploratory indications remains thin, with many potential uses lacking published trial results.

Half-life~5 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.94.71.24.12.44.0

Research Evidence

Evidence shape

Tirzepatide carries a high evidence tier, supported by robust Phase 3 clinical data for the treatment of obesity and type 2 diabetes. While the literature is extensive for these primary indications, with 211 registered trials and 27 blinded studies confirming efficacy, the vast majority of the 86 mapped indications remain exploratory or rely on single-trial data. This creates a clear divide between the well-established metabolic applications and a long tail of experimental uses that currently lack the scale or replication required to support clinical conclusions.

Depthhow much
216 registered trials
77 completed · 45 with posted results · 132 recruiting / active · combined n=32841
Breadthhow many areas
89 indications mapped
10 with results · 77 thin / exploratory · 1 animal-only · 62 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
27 blinded with results · 12 distinct sponsors · AE rows aggregated from 43 trials · 122 linked publications on registered trials
Breadth and depth234 rows captured
Human
direct clinical signal
219
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

+1 more use case below visualisation cap

Tirzepatide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
BOC Peptide
--
1000 mg×10
$320.00
$0.32/mg
2
Better Peptide
--
100 mg
$44.99
$0.45/mg
3
Peptide Technologies
unknown
50 mg
$39.99
$0.8/mg
4
Mrbeetoe
--
50 mg
$45.00
$0.9/mg
5
Lilipeptide
China
50 mg×10
$47.00
$0.94/mg
6
seacoastaminos.com
--
30 mg
$30.99
$1.03/mg

price offers can be sorted by column

1-6 of 250

Tirzepatide dosing & protocol

How Tirzepatide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 80
Typical dose
5 mg2.5 mg – 15 mg
typical
0
5 mg
10 mg
15 mg
distribution of 49 reported doses · darker = more
Frequency
weekly
Route
subQ

In research trials, tirzepatide was administered subcutaneously at weekly doses ranging from 2.5 mg to 15 mg, with a commonly used dose of 5 mg per week; no specific cycling regimen was reported.

80 sources
Clinician practice
Doctor & published-protocol guidance · n = 5
Starting dose
2.5 mg2.5 mg – 15 mg
start
0
5 mg
10 mg
15 mg
distribution of 11 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

Clinicians commonly administer 15 mg of tirzepatide subcutaneously each week, although protocols report a weekly dosing range from 2.5 mg up to 15 mg.

5 sources
Anecdotal
Community-reported real-world use · n = 133
Typical dose
2.4 mg300 µg – 15 mg
typical
0
5 mg
10 mg
15 mg
distribution of 144 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users most often cite a typical dose of 2.4 mg subcutaneously, with reported amounts spanning 300 mcg to 15 mg; one source notes a weekly regimen of 1.8 mg.

133 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO. Discontinue if pancreatitis is suspected.
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necess…
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice.
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
  • • Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. MOUNJARO is not recommended in patients with severe gastroparesis.
  • • Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor…
  • • Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedur…
Contraindications
  • • MOUNJARO is contraindicated in
  • • patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in
  • • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity rea…
  • • patients with Multiple Endocrine Neoplasia syndrome type 2. Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.
Drug interactions
  • • MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.2)

Related peptides

SemaglutideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide